Some guidelines (AFU, EAU, ESMO, NCCN, and NPV PCa) also take into consideration the mutation status of the patient and recommend starting screening at the age of 40 yr for BRCA1/2 or HOXB13 mutation carriers. This evidence concerns the gene HOXB13 and posterior cortical atrophy.